Istesso: IP : Istesso Ltd - MBS2320 Phase 2a results

(marketscreener.com) Istesso Limited ('Istesso'') today announces headline results from the Phase 2a study of its investigational drug, MBS2320, in rheumatoid arthritis ('RA'). The study was a randomised, double-blind, placebo-controlled trial for which the primary objective was to assess the safety and tolerability of MBS2320 over 12 weeks of...http://www.marketscreener.com/IP-GROUP-PLC-38908802/news/IP-Istesso-Ltd-MBS2320-Phase-2a-results-28903173/?utm_medium=RSS&utm_content=20190715